中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
5期
799-801
,共3页
反复呼吸道感染%匹多莫德%儿童%免疫功能
反複呼吸道感染%匹多莫德%兒童%免疫功能
반복호흡도감염%필다막덕%인동%면역공능
Recurrent respiratory tract infections%Pidotimod%Children%Immunological function
目的：：研究匹多莫德联合常规治疗措施治疗反复呼吸道感染患儿的疗效及对免疫调节的作用。方法：反复呼吸道感染患儿114例按入院先后顺序分为两组。对照组58例采用常规治疗，观察组56例在对照组基础上加用匹多莫德。治疗2个月后，对全部患儿随访1~6个月，观察两组患儿症状体征消失时间、临床疗效、复发情况及各项生理指标，比较两组患儿免疫功能变化。结果：观察组临床症状与肺部体征消失时间明显短于对照组(P<0.05)；总有效率为92.86%，明显高于对照组的67.24%(P<0.001)。观察组患儿上、下呼吸道感染次数明显低于对照组(P<0.05)。治疗后，观察组患儿各项免疫指标均有明显提高(P<0.01)，且明显高于对照组(P<0.05或0.01)；而对照组患儿治疗前后免疫指标比较，差异无统计学意义(P>0.05)。结论：反复呼吸道感染患儿应用匹多莫德联合常规治疗措施治疗的疗效良好，且能够有效提高患儿的免疫能力。
目的：：研究匹多莫德聯閤常規治療措施治療反複呼吸道感染患兒的療效及對免疫調節的作用。方法：反複呼吸道感染患兒114例按入院先後順序分為兩組。對照組58例採用常規治療，觀察組56例在對照組基礎上加用匹多莫德。治療2箇月後，對全部患兒隨訪1~6箇月，觀察兩組患兒癥狀體徵消失時間、臨床療效、複髮情況及各項生理指標，比較兩組患兒免疫功能變化。結果：觀察組臨床癥狀與肺部體徵消失時間明顯短于對照組(P<0.05)；總有效率為92.86%，明顯高于對照組的67.24%(P<0.001)。觀察組患兒上、下呼吸道感染次數明顯低于對照組(P<0.05)。治療後，觀察組患兒各項免疫指標均有明顯提高(P<0.01)，且明顯高于對照組(P<0.05或0.01)；而對照組患兒治療前後免疫指標比較，差異無統計學意義(P>0.05)。結論：反複呼吸道感染患兒應用匹多莫德聯閤常規治療措施治療的療效良好，且能夠有效提高患兒的免疫能力。
목적：：연구필다막덕연합상규치료조시치료반복호흡도감염환인적료효급대면역조절적작용。방법：반복호흡도감염환인114례안입원선후순서분위량조。대조조58례채용상규치료，관찰조56례재대조조기출상가용필다막덕。치료2개월후，대전부환인수방1~6개월，관찰량조환인증상체정소실시간、림상료효、복발정황급각항생리지표，비교량조환인면역공능변화。결과：관찰조림상증상여폐부체정소실시간명현단우대조조(P<0.05)；총유효솔위92.86%，명현고우대조조적67.24%(P<0.001)。관찰조환인상、하호흡도감염차수명현저우대조조(P<0.05)。치료후，관찰조환인각항면역지표균유명현제고(P<0.01)，차명현고우대조조(P<0.05혹0.01)；이대조조환인치료전후면역지표비교，차이무통계학의의(P>0.05)。결론：반복호흡도감염환인응용필다막덕연합상규치료조시치료적료효량호，차능구유효제고환인적면역능력。
Objective:To study the efficacy and immunoregulation of pidotimod combined with routine treatment in the children with recurrent respiratory tract infections. Methods:Totally 114 cases of children with recurrent respiratory tract infections were divid-ed into the control group and the treatment group according to the sequence of hospitalization. The 58 patients in the control group re-ceived the conventional treatment, while the 56 patients in the treatment group were given pidotimod additionally. After two-month treatment, all the children were given 1 -6-month follow-up, and the symptom disappearance time, clinical efficacy, recurrence, physiological indices and change of immunological function in the two groups were observed and compared. Results:The disappearance time of symptom and lung physical signs in the observation group was much shorter than that in the control group (P<0. 05);the total effective rate of the observation group was 92. 86%, which was significantly higher than that of the control group (67. 24%, P <0. 001). The number of upper and lower respiratory tract infections in the observation group was significantly lower than that in the con-trol group (P<0. 05). After the treatment, the immune parameters in the observation group were significantly improved (P<0. 01), which were significantly higher than those in the control group (P<0. 05 or P<0. 01). The immune parameters before and after the treatment in the control group showed no statistically significant difference (P>0. 05). Conclusion:Pidotimod combined with routine treatment in the children with recurrent respiratory tract infections exhibits promising efficacy, which can improve immunity effectively.
